Posts

Showing posts with the label scientist

Subscribe Now!

Syngene International Ltd. FY2020-21 Annual Report Key Takeaways

Image
Syngene International Ltd. FY2020-21 Annual Report Key Takeaways  In continuation of my previous blog here is the updated version l ink to Initial Blog -  https://myweekendspot.blogspot.com/2020/10/syngene-next-giant-player-for-cdmo.html Company Overview Incorporated in 1994 as a subsidiary of Biocon, Syngene International (SIL) is a leading contract research organization (CRO), which supports R&D programs of global innovative companies.   SIL offers outsourced services to support discovery and development for organizations across industrial sectors like pharmaceuticals, biopharmaceuticals, nutraceuticals, animal health, agrochemicals, etc. It currently caters to 400+ global players including Bristol-Myers Squibb (BMS), Abbott, Baxter, and Amgen, among others. SIL derives 95% of its revenues from exports.   Syngene continued to build on its integrated drug discovery and development portfolio during the year, including a five-year collaboration with 3DC,...

Syngene - Next Giant Player for CDMO

Image
  Syngene International Limited -  Company Overview Twitter Handle: @shuchi_nahar Link to FY 2020-21 Annual Report takeaways - https://myweekendspot.blogspot.com/2021/10/syngene-international-ltd-fy2020-21.html 1. Company Overview Incorporated in 1994 as a subsidiary of Biocon, Syngene International (SIL) is a leading contract research organization (CRO), which supports R&D programs of global innovative companies   SIL offers outsourced services to support discovery and development for organizations across industrial sectors like pharmaceuticals, biopharmaceuticals, nutraceuticals, animal health, agro-chemicals, etc. It currently caters to 293 global players including Bristol-Myers Squibb (BMS), Abbott, Baxter and Amgen, among others. SIL derives 95% of its revenues from exports. Mangalore API plant is constructed and validation is expected to be completed in FY21.  In FY20, Syngene extended its biologics discovery and preclinical research capabi...